Graphic pathographies can illustrate how overreliance on statistics can obscure the clinical relevance of patients’ experiences of anxiety when they’re presented with prognoses.
Farmworkers can become ill due to toxic exposure in their work environments. Recommending specific restrictions, educating patients on protection strategies, and partnering with agribusiness owners and allied health workers can drive development of alternatives to agricultural practices with health risks.
Large precision health initiatives like the National Institutes of Health’s All of Us campaign raise important ethical questions about consent, privacy, and inclusivity. This month on Ethics Talk, we explore with Dr Katie Johansen Taber and Ysabel Duron strategies for protecting participants and ensuring that diverse communities are represented.
Elizabeth Boskey, PhD, MPH, MSSW, Amir Taghinia, MD, and Oren Ganor, MD
Training should be implemented to respond to clinical staff members’ concerns about trans patients occupying sex-segregated spaces and to help mitigate anti-trans bias.
Rachel Koch, MD, John G. Meara, MD, DMD, MBA, and Anji E. Wall, MD, PhD
Single-procedure interventions with minimal follow-up and clear quality-of-life gain are well suited for surgical mission trips. But not all risks and benefits are easily assessed.
How do we determine what a fair price for a life-saving prescription medication should be? This month, we discuss what is means for a price to be “fair” and explore the current legal and economic landscape of prescription drug pricing in the US.
Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.